61. Familiar Hypercholesterolemia - West Virginia familiar hypercholesterolemia, West Virginia, 1800-982-8242 Extension 4816.WV DHHR BPH OEHP HP. Addressing familial hypercholesterolemia http://www.wvdhhr.org/bph/oehp/hp/cardio/fh.htm

Who is at risk? Why your family history is important When, Where and How to get tested. Managing FH ... Seeking Specialist Consultation For more information, call the toll free number below: 1-800-982-8242 Extension 4816 WV DHHR BPH OEHP ... HP Addressing Familial Hypercholesterolemia What is FH? FH or Familial Hypercholesterolemia is an inherited disorder which causes cholesterol levels to be elevated. One in every 250-500 people have FH. People with this inherited disorder lack LDL (low density lipoproteins) receptors or molecules which can identify cholesterol. LDL receptors on the cell membrane take cholesterol into the cell and break it down, so that the HDL (high density lipoproteins) can carry the cholesterol to the liver to be excreted from the body People with FH have fewer receptors on their cell membranes and therefore have elevated cholesterol in their blood, because the cholesterol cannot get into the cell to be carried to the liver. Thus, fewer receptors lead to elevated cholesterol which causes plaque formation and coronary artery disease. The elevated cholesterol levels in the blood cause an increased risk of early death secondary to heart disease. For example, people with FH have an increased chance of having a heart attack at an extremely early age. Even without other risk factors such as obesity, men may have a heart attack when they are 40-55 years old and women may have a heart attack when they are 50-65 years old.

62. ACLS -- Sign In Page familial hypercholesterolemia (FH) is the most common genetic disorder leading to Patients with familial hypercholesterolemia (FH) have elevated http://www.annclinlabsci.org/cgi/content/full/32/1/50

HOME HELP FEEDBACK SUBSCRIPTIONS ... SEARCH QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This item requires a subscription to Annals of Clinical and Laboratory Science Online. Full Text HDL Cholesterol Levels in Patients with Molecularly Defined Familial Hypercholesterolemia Miltiadous et al. Ann Clin Lab Sci. This Article Abstract Full Text (PDF) Alert me when this article is cited ... Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager PubMed PubMed Citation Articles by Miltiadous, G. Articles by Elisaf, M. To view this item, select one of the options below: Sign In User Name Sign in without cookies. Can't get past this page? Help with Cookies. Need to Activate? Password Forgot your user name or password? Purchase Short-Term Access Pay per Article - You may access this article (from the computer you are currently using) for 7 days for US$7.00 Pay for Admission - You may access all content in Annals of Clinical and Laboratory Science Online (from the computer you are currently using) for 7 days for US$25.00.

63. HDL Cholesterol Levels In Patients With Molecularly Defined Familial Hypercholes familial hypercholesterolemia (FH) is the most common genetic disorder leading Keywords HDL cholesterol, familial hypercholesterolemia, apoE genotype, http://www.annclinlabsci.org/cgi/content/abstract/32/1/50

HOME HELP FEEDBACK SUBSCRIPTIONS ... TABLE OF CONTENTS QUICK SEARCH: [advanced] Author: Keyword(s): Year: Vol: Page: This Article Full Text Full Text (PDF) Alert me when this article is cited ... Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager PubMed PubMed Citation Articles by Miltiadous, G. Articles by Elisaf, M. Association of Clinical Scientists HDL Cholesterol Levels in Patients with Molecularly Defined Familial Hypercholesterolemia George Miltiadous Marios A. Cariolou and Moses Elisaf Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece Molecular Genetics Department,The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus Address correspondence to Moses Elisaf, M.D., F.R.S.H., Department of Internal Medicine, Medical School, University of Ioannina, GR 451 10, Ioannina, Greece; tel 306 519 7509; fax 306 514 5944; e-mail Familial hypercholesterolemia (FH) is the most common genetic disorder leading to premature atherosclerosis. Typically, it

64. Biochip For The Diagnosis Of Familial Hypercholesterolemia Hypercholesterolemia patients now have a new method of diagnosis that enablesthem to know for sure if they are suffering from Familial Hypercholesteloremia http://www.innovations-report.de/html/berichte/medizin_gesundheit/bericht-25652.

Weitere Förderer des Forums Content Partner des Forums Medizin Gesundheit Progenika S.A. Biochip for the diagnosis of Familial Hypercholesterolemia Hypercholesterolemia patients now have a new method of diagnosis that enables them to know for sure if they are suffering from Familial Hypercholesteloremia (FH) or not. The new tool, known as Lipochip, is the first biochip for the diagnosis of Familial Hypercholesteloremia (a pathology that affects some 100,000 persons in Spain). The majority of those currently suffering from FH are not diagnosed as such. It is calculated that less than 30% of them have received a correct diagnosis with the majority receiving inadequate or inappropriate treatment. Moreover, when the illness is diagnosed, it is often too late as the patient a premature cardiovascular event which may be life-threatening. Lipochip enables the early diagnosis of a large number of patients in a short space of time. In this way, cardiovascular illnesses can be prevented, these pathologies appearing in more than half of the patients affected by FH before 55 years of age. Amongst those between 20 and 39 years of age who suffer from Familial Hypercholesterolemia, mortality due to a coronary pathology is 100 times greater than amongst those without FH. The importance of early diagnosis of FH with Lipochip lies in this high incidence of level of premature cardiovascular illnesses amongst FH patients. Without the correct diagnosis and treatment, many patients die between 35 and 65 years of age, and seven out of ten will suffer myocardiac attack before their sixtieth birthday. However, with early diagnosis and treatment, the survival rate and quality of life of patients improves, as these coronary events are greatly diminished. This also reduces hospital costs as there are less cardiovascular events amongst patients being suitably diagnosed and treated.

65. Familial Hypercholesterolemia familial hypercholesterolemia. Treating FH. Treatment options now exist for FH,based on the accumulated knowledge of cholesterol metabolism. http://www.hhmi.org/biointeractive/museum/exhibit98/content/d7info.html

Familial Hypercholesterolemia Treating FH Treatment options now exist for FH, based on the accumulated knowledge of cholesterol metabolism. Heterozygous people can take preventive measures, such as choosing a low-fat, low-cholesterol diet. Drugs are also available to lower blood cholesterol. Treatment for FH homozygous people may include regular apheresis, a process that removes LDL from blood. Can gene therapy help patients with FH? Some researchers are working to treat diseases by correcting defective genes. James Wilson, a former HHMI investigator, developed such a procedure called gene therapy for people with FH. In the first clinical trial, Wilson removed cells from the patient's liver, grew them on 800 culture plates, and "infected" them with a virus containing the gene for normal LDL receptors. Some of the cultured liver cells accepted the new gene. The "transgenic" cells were injected directly back into the patient's liver, where they produced LDL receptors. The LDL levels in the patient's blood dropped 15 to 30 percent and stayed down for 6 months. Since then, at least four more patients have undergone the experimental procedure. So far, the approach appears promising, but more research is needed to develop a broadly practical treatment and achieve a permanent cure.

66. Homozygous Familial Hypercholesterolemia - Evaluation, Treatment And Research At The National Heart, Lung and Blood Institute is actively seeking patients withHomozygous familial hypercholesterolemia to receive free evaluation and/or http://patientrecruitment.nhlbi.nih.gov/LDL500.aspx

HOME SITE INDEX CONTACT US Patient Recruitment - Homozygous Familial Hypercholesterolemia TIPS ADVANCED SEARCH Home Clinical Trials ... Patient Recruitment Research Studies Homozygous Familial Hypercholesterolemia Research Study LDL > 500 mg/dL Research Study Homozygous Familial Hypercholesterolemia Research Study If you have homozygous familial hypercholesterolemia (FH), you are invited to participate in a study that will evaluate the development and follow the natural history of atherosclerosis in your disorder. A variety of clinical and research techniques will be used to assess and follow the development of atherosclerosis. Recommendations for treatments will be provided based upon these findings. Persons with homozygous familial hypercholesterolemia typically have a total and low density lipoprotein (LDL) cholesterol concentration greater than 700 mg/dL with normal triglycerides. Cholesterol deposits called xanthomas are frequently present in the first few years of life and are located on the elbows, knees, between the webs of the fingers and on the Achilles tendons. Eligible persons will undergo a comprehensive cardiac evaluation. All patients will remain under the care of their own physician who will receive results of the laboratory and diagnostic tests. In most cases, you will be invited back for yearly evaluations. There is no cost to you for travel or medical testing.

67. Departement Of Cardiology Faculty Of Medicine, University Of Indonesia familial hypercholesterolemia AND COMPLICATIONS. Andria Priyana. Introduction.familial hypercholesterolemia (FH) is an autosomal dominant genetic disorder http://www.kardiologi-ui.com/newsread.php?id=121

68. IngentaConnect High Risk/high Priority: Familial Hypercholesterolemia - A Paradi familial hypercholesterolemia provides an excellent model for Familialhypercholesterolemia should serve as a paradigm of molecular medicine we http://www.ingentaconnect.com/content/els/15675688/2002/00000002/00000004/art000

Home About Ingenta Ingenta Labs Help For Publishers Why go online? Why choose IngentaConnect? Why choose CustomConnect? Access and authentication ... Contact us For Researchers About IngentaConnect Search and browse Publications available Accessing articles ... Register For Librarians Why choose IngentaConnect? Why choose IngentaConnect Premium? Activating Subscriptions Purchasing articles ... Browse Publications High risk/high priority: familial hypercholesterolemia - a paradigm for molecular medicine Author: Schuster H. Source: Atherosclerosis, Supplements , Volume 2, Number 4, 1 April 2002, pp. 27-32(6) Publisher: Elsevier Science View Table of Contents full text options Keywords: Familial hypercholesterolemia Molecular characterization Disease prevention Language: English Document Type: Research article DOI: Affiliations: Infogen GmbH and Max Delbruck Center, Humboldt University, , Berlin, Germany Access to this article is through a website external to IngentaConnect You may be required to register and activate access/purchase before you can obtain the full text.

69. HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS ASSOCIATED WITH LARGER LDL SIZE FO OBJECTIVES familial hypercholesterolemia (FH) is a genetic disorder associatedwith raised plasma LDLcholesterol levels and premature coronary heart http://www.ccs.ca/society/congress2002/abstracts/abs/a157.htm

Return to Table of Contents HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IS ASSOCIATED WITH LARGER LDL SIZE FOR ANY GIVEN FASTING TRIGLYCERIDE CONCENTRATION I Lemieux, P Perron, G Tremblay, J Bergeron, P Couture, B Lamarche, D Gaudet, JP Després Québec OBJECTIVES: Familial hypercholesterolemia (FH) is a genetic disorder associated with raised plasma LDL-cholesterol levels and premature coronary heart disease (CHD). Although it has been suggested that LDL size could further increase the CHD risk resulting from an elevated LDL concentration, factors controlling LDL size in FH patients are not fully understood. Therefore, the objectives of the present study were to compare LDL size in FH vs nonFH patients and to study its relationship with known correlates of LDL size such as abdominal obesity (waist girth) and triglyceride (TG) levels. METHODS: After exclusion of patients with fasting TG and glucose levels greater than 4.5 mmol/L and 7.0 mmol/L respectively, a sample of 112 male patients (46.7 ± 12.6 years of age) with a clinical and/or molecular diagnosis of heterozygous FH was compared to a group of 305 nonFH men (42.3 ± 11.9 years). LDL size was assessed by 2-16% polyacrylamide gel electrophoresis. RESULTS: FH patients were characterized by the expected differences in their plasma lipid profile including substantially higher cholesterol (+65.8%), LDL-cholesterol (+88.9%) and apo B (+30.6%) levels than non FH men despite the fact that they had lower body mass index (-8.1%) and waist circumference (-5.4%) values than nonFH controls (p

70. Entrez PubMed Fibroblasts from patients with homozygous familial hypercholesterolemia (FH), adisease characterized by accelerated atherogenesis, are known to lack http://www.immunityageing.com/pubmed/2963664

My NCBI [Sign In] [Register] All Databases ... Books Search PubMed Protein Nucleotide Structure Genome Books CancerChromosomes Conserved Domains 3D Domains Gene Genome Project GENSAT GEO Profiles GEO DataSets HomoloGene Journals MeSH NCBI Web Site NLM Catalog OMIA OMIM PMC PopSet Probe PubChem BioAssay PubChem Compound PubChem Substance SNP Taxonomy UniGene UniSTS for Limits Preview/Index History Clipboard Details About Entrez Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Mobile NLM Catalog NLM Gateway ... PubMed Central Display Summary Brief Abstract Citation MEDLINE XML UI List LinkOut ASN.1 Related Articles Cited Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Gene (GeneRIF) Links Genome Links Project Links GENSAT Links GEO Profile Links HomoloGene Links Nucleotide Links OMIA Links OMIM Links BioAssay Links Compound Links Compound via MeSH Substance Links Substance via MeSH PMC Links Cited in PMC PopSet Links Probe Links Protein Links SNP Links Structure Links UniGene Links UniSTS Links Show Sort by Author Journal Pub Date Send to Text File Clipboard E-mail Order All: 1 Review: Biochim Biophys Acta.

71. Oligonucleotide Ligation Assay (OLA) For The Diagnosis Of Familial Hypercholeste Molecular genetics of the LDL receptor gene in familial hypercholesterolemia . explain one third of familial hypercholesterolemia in a German sample. http://www.nature.com/nbt/journal/v14/n10/abs/nbt1096-1279.html

@import "/nbt/style.css"; NATURE.COM NEWS@NATURE.COM NATUREJOBS NATUREEVENTS ... Help E-MAIL: PASSWORD: Save password Forgotten password? SEARCH JOURNAL Advanced search Journal home Archive Table of Contents ... For librarians NPG Resources Bioentrepreneur The Nature Biotechnology Directory Nature Reviews Drug Discovery Nature ... Browse all publications Research Article Nature Biotechnology doi:10.1038/nbt1096-1279 Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia Heike Baron , Steven Fung , Atakan Aydin , Friedrich C. Luft Applied Biosystems Division of Perkin Elmer, Foster City, CA 94404. Corresponding author. REFERENCES Kannel, W.B., Castelli, W.P., Gordon, T., and McNamara, P.M. 1971. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. Ann. Intern. Med PubMed ISI ChemPort Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet PubMed ISI Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., Macfarlane, P.W., et al. 1996. Prevention of coronary heart disease with pravastatin in men with hyper-cholesterolemia. N. Engl. J. Med

72. Familial Hypercholesterolemia Federally Funded Research on familial hypercholesterolemia. EJournals PubMedCentral Finding Nutrition Studies on familial hypercholesterolemia http://www.icongrouponline.com/health/Familial_Hypercholesterolemia_Ph.html

ICON Health Publications Official Health Sourcebooks Search ICON Health Titles: FAMILIAL HYPERCHOLESTEROLEMIA A Bibliography, Medical Dictionary, and Annotated Research Guide to Internet References (hypercholesterolemic xanthomatosis; type II hyperlipoproteinemia) P A P E R B A C K Paperback Book Paperback Book Order by phone: 800-843-2665 (within USA) 1-201-272-3651 (from outside USA) Paperback Book Shipped in 3 to 5 business days E B O O K Electronic File * E-Book version sent via e-mail in 2 business days Pages Price $34.95(USD) ISBN Published Synopsis In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with familial hypercholesterolemia is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. Related Conditions/Synonyms hypercholesterolemic xanthomatosis; type II hyperlipoproteinemia

73. LIPOSORBER® LDL Apheresis - Treatment Option For Familial Hypercholesterolemia familial hypercholesterolemia) for whom diet has been ineffective and maximum University of Michigan Treating familial hypercholesterolemia with LDL http://www.liposorber.com/

The Liposorber LA-15 LDL Apheresis System is approved by the FDA and indicated for use to acutely remove LDL-C from the plasma of the following high-risk patient populations (ex. Familial Hypercholesterolemia) for whom diet has been ineffective and maximum drug therapy (such as Statins) has either been ineffective or not tolerated: Examples of Current Liposorber Treatment Sites Near You (alphabetical order by state, city) Cedars-Sinai Medical Center Los Angeles, CA Emory University Atlanta, GA Evanston Hospital: LDL Apheresis Evanston, IL University of Kansas Medical Center Kansas City, KS University of Michigan: Treating Familial Hypercholesterolemia with LDL Apheresis Ann Arbor, MI Mayo Clinic Rochester, MN University of North Carolina: Only Lipid Clinic in NC to offer LDL Apheresis Chapel Hill, NC

74. Familial Hypercholesterolemia Probed - MIT News Office Bostonarea scientists, including two at the Whitehead Institute for BiomedicalResearch, have found why defects occur in the receptors for the low-density http://web.mit.edu/newsoffice/1996/hypercholesterolemia-0911.html

Skip to content massachusetts institute of technology news office advanced search news recent research campus by topic ... archives services request images subscribe submit news promote news ... media inquiries about us news office info MIT background contact Familial hypercholesterolemia probed Seema Kumar, Whitehead Institute September 11, 1996 Familial hypercholesterolemia (FH), a genetic disease characterized by high levels of cholesterol and early mortality, is caused by defects in the receptor for the low-density lipoprotein (LDL)the "bad" cholesterol. Now, Boston-area scientists including two at the Whitehead Institute for Biomedical Research have found that this occurs because mutations in the LDL receptor prevent the protein from folding into its normal shape. This in turn impedes the receptor's ability to bind bad cholesterol and remove it from the bloodstream, causing the hypercholesterolemia. FH is an autosomal dominant trait, meaning that a child born to an affected parent has a 50 percent chance of inheriting the gene. About 1 in 500 people are heterozygous for FH-they have one abnormal and one normal copy of the LDL receptor gene-making FH one of the most common inborn errors of metabolism. At birth, FH-heterozygous people have a twofold increase in cholesterol levels, and they develop coronary heart disease in middle age. Homozygotes (people who have two abnormal copies of the LDL receptor gene) number about one in a million and have a severe form of the disease in which coronary heart disease begins during childhood and causes death by age 20.

75. Lipid Digestion And Lipoproteins Type II (familial hypercholesterolemia, FH), 4 classes of LDL receptor defect,reduced LDL clearance leads to hypercholesterolemia, resulting in http://www.dentistry.leeds.ac.uk/biochem/thcme/lipoproteins.html

Intestinal Uptake of Lipids Composition of Lipoprotein Complexes Classification of Apoproteins Chylomicrons ... Return to Medical Biochemistry Home Page Intestinal Uptake of Lipids In order for the body to make use of dietary lipids, they must first be absorbed from the small intestine. Since these molecules are oils, they are essentially insoluble in the aqueous environment of the intestine. The solubilization (or emulsification) of dietary lipids is thereforeaccomplished by means of bile salts, which are synthesized from cholesterol in the liver and then stored in the gallbladder; they are secreted following the ingestion of fat. The emulsification of dietary fats renders them accessible to pancreatic lipases (primarily lipase and phospholipase A ). These enzymes, secreted into the intestine from the pancreas, generate free fatty acids and a mixtures of mono- and diacylglycerols from dietary triacylglycerols. Pancreatic lipase degrades triacylglycerols at the 1 and 3 positions sequentially to generate 1,2-diacylglycerols and 2-acylglycerols. Phospholipids are degraded at the 2 position by pancreatic phospholipase A releasing a free fatty acid and the lysophospholipid. The products of pancreatic lipases then diffuse into the intestinal epithelial cells, where the re-synthesis of triacyglycerols occurs.

76. Hypercholesterolemia, Familial Clinical Outcome of Patients with familial hypercholesterolemia and CoronaryArtery Disease Undergoing Partial Ileal Bypass Surgery Clinical Outcome of http://www.gfmer.ch/genetic_diseases_v2/gendis_detail_list.php?cat3=124

77. Familial Hypercholesterolemia A dominantly inherited genetic condition that results in markedly elevated (lowdensitylipoprotein) cholesterol levels beginning at birth, and resulting in http://www.ehendrick.org/healthy/000392.htm

Injury Disease Nutrition Poison ... Prevention Familial hypercholesterolemia Definition A dominantly inherited genetic condition that results in markedly elevated LDL (low-density lipoprotein) cholesterol levels beginning at birth, and resulting in heart attacks at an early age. Alternative Names Type II hyperlipoproteinemia; Hypercholesterolemic xanthomatosis; Low density lipoprotein receptor mutation Causes Affected people have consistently high levels of low-density lipoprotein, which leads to premature atherosclerosis of the coronary arteries. Typically in affected men, heart attacks occur in their 40s to 50s, and 85% of men with this disorder have experienced a heart attack by age 60. The incidence of heart attacks in women with this disorder is also increased, but delayed 10 years later than in men. Individuals from families with a strong history of early heart attacks should be evaluated with a lipid screen. Proper diet, exercise, and the use of newer drugs can bring lipids down to safer levels. It is possible for a person to inherit two genes for this disorder. This magnifies the severity of the condition.

78. Arquivos Brasileiros De Cardiologia - familial hypercholesterolemia is characterized by high serum levels of total The clinical presentation of familial hypercholesterolemia is through http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2000000700005

79. Familial Hypercholesterolemia - Definition Of Familial Hypercholesterolemia In T Definition of familial hypercholesterolemia in the Medical Dictionary and Thesaurus.familial hypercholesterolemia explanation. Information about familial http://medical-dictionary.thefreedictionary.com/familial hypercholesterolemia

Domain='thefreedictionary.com' word='familial hypercholesterolemia' Your help is needed: American Red Cross The Salvation Army join mailing list webmaster tools Word (phrase): Word Starts with Ends with Definition subscription: Dictionary/ thesaurus Computing dictionary Medical dictionary Legal dictionary Financial dictionary Acronyms Columbia encyclopedia Wikipedia encyclopedia Hutchinson encyclopedia familial hypercholesterolemia Also found in: Dictionary/thesaurus Wikipedia 0.03 sec. Page tools Printer friendly Cite / link Email Feedback familial hypercholesterolemia n. See type II familial hyperlipoproteinemia See hypercholesterolemia Mentioned in familial hypercholesterolemia with hyperlipemia type III familial hyperlipoproteinemia Medical browser Full browser familial broad-beta hyperlipoproteinemia familial dysautonomia familial fat-induced hyperlipemia familial hemiplegic migraine ... familial hyperbetalipoproteinemia and hyperprebetalipoproteinemia familial hypercholesterolemia familial hypercholesterolemia with hyperlipemia familial hyperchylomicronemia familial hyperchylomicronemia with hyperprebetalipoproteinemia familial hyperlipoproteinemia ... familial hyperbetalipoproteinemia and hyperprebetalipoproteinemia familial hypercholesterolemia familial hypercholesterolemia with hyperlipemia familial hyperchylomicronemia familial hyperchylomicronemia with hyperprebetalipoproteinemia familial hyperlipoproteinemia ... Familial Partial Lipodystrophy, Dunnigan Type

80. Familial Hypercholesterolemia Lahiri Koushik, Lahiri Bhabesh Chandra - Indian J Lahiri K, Lahiri B. familial hypercholesterolemia. Homozygous familialhypercholesterolemia. Indian J Dermatol Venereol Leprol 2000;66331332. http://www.ijdvl.com/article.asp?issn=0378-6323;year=2001;volume=67;issue=4;spag

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 4     61-80 of 103    Back | 1  | 2  | 3  | 4  | 5  | 6  | Next 20